tert-Butyl (2-(2-azidoethoxy)ethyl)(2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)-2-oxoethoxy)ethoxy)ethoxy)ethyl)carbamate

Catalog No. :
ACLRNG924
CAS No. :
2415736-86-4
Molecular Formula :
C30H43N7O10
Molecular Weight :
661.71

IUPAC Name:tert-butyl (2-(2-azidoethoxy)ethyl)(2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)-2-oxoethoxy)ethoxy)ethoxy)ethyl)carbamate

tert-Butyl (2-(2-azidoethoxy)ethyl)(2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)-2-oxoethoxy)ethoxy)ethoxy)ethyl)carbamate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl (2-(2-azidoethoxy)ethyl)(2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)-2-oxoethoxy)ethoxy)ethoxy)ethyl)carbamate
IUPAC Nametert-butyl (2-(2-azidoethoxy)ethyl)(2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)-2-oxoethoxy)ethoxy)ethoxy)ethyl)carbamate
Molecular FormulaC30H43N7O10
Molecular Weight661.71
SMILESO=C(OC(C)(C)C)N(CCOCCN=[N+]=[N-])CCOCCOCCOCC(NC1=CC=CC2=C1CN(C(CC3)C(NC3=O)=O)C2=O)=O
InChI KeyJEEBPVQLLIQHIV-UHFFFAOYSA-N
CAS No.2415736-86-4

Synthetic Route by SureRoute

1. ACLRNG924 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACFVXI513 route compound structure diagram
    ACFVXI513191732-72-6 In Stock
  4. Then
  5. ACLRNG924 route product structure diagram
    ACLRNG9242415736-86-4
Inquiry

2. ACLRNG924 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACFVXI513 route compound structure diagram
    ACFVXI513191732-72-6 In Stock
  4. Then
  5. ACLRNG924 route product structure diagram
    ACLRNG9242415736-86-4
Inquiry

Comments (0)